Sign in

drfranciscomd.bsky.social

@drfranciscomd.bsky.social
557 followers 337 following 80 posts

Practicing Hematologist & Oncologist + nerd = me. I break down cancer news and treatments, one Middle-earth metaphor at a time. Join me for facts, laughs, and Gandalf-level wisdom. Stanford ->MSKCC -> IU -> UA -> Kaiser SF -> Intermountain Alta View

PostsRepliesMedia
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 18/02/2025
Spent the last few weeks working on my latest essay. I have Spent years in healthcare. I’ve seen what happens when profit overshadows care. My new Medium post explains why we need robust public health solutions. Let’s fight for better outcomes—together! #Medsky #Oncology #HealthPolicy
medium.com
Who’s Really Healing Us? The Dangers of Dismantling Government-Led Healthcare
I’ve spent my career in healthcare, and lately it feels like I’m watching a slow-motion demolition of the very structures that have…
7151
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 12/02/2025
ctDNA is like the Palantíri—seeing-stones revealing hidden truths. Just as they offered glimpses into distant events, ctDNA uncovers cancer’s covert activities, helping us anticipate recurrence. Knowledge is power! 🔮🛡️ #LOTRNerd #OncologyWithPurpose
060
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 12/02/2025
The NCCN now recognizes ctDNA as a high-risk factor for recurrence in colon/rectal cancer and as a tool in Merkel cell carcinoma. While promising, routine use outside trials isn’t recommended yet. ctDNA’s role in personalized care is evolving! 🧬✨ #ColonCancer #Oncology #Medsky #Research
onclive.com
NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines
The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.
2110
Reposted by @drfranciscomd.bsky.social
Jan Kirsch, M.D., M.P.H. @drjanicekirsch.bsky.social · 08/02/2025
SEASONAL INFLUENZA SURGING. Please take care The 2024–2025 flu season — which has sickened an estimated 24 million Americans so far — is in full swing. However, there’s more to come before the season peaks www.today.com/health/cold-...
today.com
Where is flu surging in the US? Some hospitals are overwhelmed in states with high rates
Flu has surged to high levels across the US, straining hospitals. Experts discuss 2024-25 flu season trends, symptoms to watch for, and how to stay safe.
46623
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 08/02/2025
A personalized cancer vaccine is like the Nauglamír, the Dwarven-crafted necklace remade to hold a Silmaril for Eärendil. Each piece was unique, but when tailored for its purpose, it became a beacon of hope. Similarly, these vaccines are custom-forged to target cancer with precision. 💎⚔️
020
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 08/02/2025
Personalized cancer vaccines are making waves! A new study shows a novel vaccine may be effective in stage III/IV clear cell RCC, offering hope for tailored treatment. Could this be the future of RCC care? Would anti vaxxers even accept this or still prefer Ivermectin?🧬✨ #Cancer #Oncology #Medsky
ascopost.com
Novel Personalized Cancer Vaccine May Be Effective in Patients With Stage III and IV Clear Cell Renal Cell Carcinoma
Researchers have examined whether a novel personalized cancer vaccine can improve outcomes in patients with stage III or IV clear cell renal cell carcinoma.
180
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 05/02/2025
Tracking TILs during radiation therapy is like the watchful Ents of Fangorn—silent observers who notice changes others miss. Just as they stir when the forest is threatened, monitoring TILs helps oncologists adjust treatment, making care more precise and adaptive. 🌳🔍 #LOTRNerd #OncologyWithPurpose
020
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 05/02/2025
A new study suggests tracking tumor-infiltrating lymphocytes (TILs) during radiation therapy may offer insights into prognosis and guide personalized treatment in breast cancer. Monitoring immune responses could refine therapy strategies for better outcomes. 🧬✨ #BreastCancer #CancerResearch
redjournal.org
Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy
Tumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy with immunotherapy, little is known abou...
140
Reposted by @drfranciscomd.bsky.social
Dr Lindsey Fitzharris @drlindseyfitz.bsky.social · 01/02/2025
With science falling under increasing attack, this medical historian is here to remind people of the power of #vaccines. THREAD🧵 Hard-hitting polio advert from 1958. In the first half of the 20th century, polio was the leading cause of death in children and young adults. 1/7
An advertisement for the polio vaccine which reads: "they all got vaccine except dad...don't take a chance...take your polio shots!" It depicts a photo of a family gathered around a father who is in an iron lung.
18085632745
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 28/01/2025
In Middle-earth terms, fam-trastuzumab deruxtecan-nxki is like the Dawnless Day before the Ride of the Rohirrim. Just as the shadow of Mordor spread over Gondor, patients with HER2-positive tumors faced limited options—but now, a new charge against the darkness begins. 🌅⚔️
020
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 28/01/2025
The FDA has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adults with unresectable or metastatic HER2-positive solid tumors who have received prior treatments . This approval offers new hope for patients with limited options. I love this drug! #BreastCancer #Oncology
fda.gov
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HE...
250
Reposted by @drfranciscomd.bsky.social
Maximus @maximustm.bsky.social · 26/01/2025
I was set to enter a clinical trial in February. It's since been canceled. You are spot on with "cancer itself will not agree to such a delay." #Cansky
32811
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 27/01/2025
There is clearly one right answer here. I’m definitely not biased 🙄
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 27/01/2025
This week’s essay is inspired by the incredible support staff who make cancer care possible—and the tough reality of working without them. It takes a team to guide patients through their journey. Let’s not forget the value of every member of our healthcare Fellowship🧬✨ #Cancer #Oncology #Healthcare
medium.com
It Takes a Fellowship: Why Support Staff Are the Unsung Heroes of Cancer Care
In my years of practice as an oncologist, I’ve come to realize that cancer care is not just about treating a disease — it’s about guiding people through one of the most challenging journeys of their…
130
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 25/01/2025
This came out decades ago but remains a true and simple depiction of grief.
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 24/01/2025
In Middle-earth terms, aspirin in this trial is like the Fellowship’s attempt to cross Caradhras. A well-reasoned effort with potential merit, but ultimately, the path did not lead to success, and another way had to be sought. Aspirin was well-tolerated but didn’t significantly improve OS. 🗻⚔️
021
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 24/01/2025
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): a phase 3 international trial.’ This study found that aspirin 200 mg daily for 3 years was well tolerated but did not significantly improve disease-free survival 🧬✨ #Oncology #Cancer
130
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 20/01/2025
Non-medical post: Onyx Storm dropped today, and my wife is already several chapters in. Every so often, I hear her say, ‘Just one more chapter,’ but we all know that’s book lover code for ‘leave snacks and back away slowly.’ It’s an art form, really. 📚😅 #OnyxStorm
040
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 19/01/2025
My weekly essay is up, inspired by the countless moments this week spent calming anxious patients after early test results. Should oncologic results wait until the doctor’s appointment? Is instant access helping or hurting? Share your thoughts. 🧬✨ #Oncology #Hematology #Medsky
medium.com
Stop the Spiral: How Early Test Results Are Hurting Cancer Patients
As an oncologist, I’ve seen it happen more times than I can count. A patient gets their imaging results or tumor marker levels through their online portal days before we’re scheduled to meet. By the…
5103
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 18/01/2025
In Middle-earth terms, sotorasib with panitumumab is like the reforging of Andúril—created to conquer what was thought invincible. KRAS mutations, like Sauron, seemed unstoppable, but this combination cuts through the darkness, bringing hope to advanced colorectal cancer patients. ⚔️✨ #Oncology
041
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 18/01/2025
The FDA has approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. This combo therapy tackles a previously ‘undruggable’ mutation, offering new hope for advanced cases. A major milestone in precision oncology! 🧬✨ #CancerResearch #OncologyNews
ascopost.com
FDA Approves Sotorasib With Panitumumab for <em>KRAS</em> G12C–Mutated Colorectal Cancer
On January 16, the FDA approved a KRAS G12C inhibitor in combination with a monoclonal antibody for adult patients with KRAS G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved...
151
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 15/01/2025
+1 on this wish list
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 15/01/2025
Throw in prior auths and bureaucratic delay as the cherry on top and people often debate which is more traumatic the cancer itself or the financial toxicity that comes with it. The system as it stands is not helping the patient
030
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 15/01/2025
This is more association than causation, based on a small study of poultry workers—not the general population thus confounders abound. I do agree with him in the bigger picture with his other videos that I agree processed foods are carcinogenic, we shouldn’t overextend conclusions from limited data.
100
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 15/01/2025
Source?
100
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 14/01/2025
Datopotamab deruxtecan in NSCLC is like the Huorns’ intervention at Helm’s Deep—subtle but devastating. While unseen in the battle’s chaos, the Huorns eradicated Saruman’s retreating forces with precision and power. 🌲⚔️ #LOTR #Oncology
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 14/01/2025
Phase II TROPION-Lung04 study indicate that datopotamab deruxtecan shows promising efficacy and a manageable safety profile in patients with advanced or metastatic non–small-cell lung cancer (NSCLC) who have been previously treated. ADCs are coming! #LungCancer #Oncology
ascopubs.org
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
PURPOSEDatopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II tr...
110
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 14/01/2025
What do you think? How would this fair if compared to OpenAI O3 model?
000
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 14/01/2025
As a former Kaiser Fellow who rotated through the Stanford BMT unit and a proud Stanford Master’s alum, I’m always in awe of how far cellular therapies have advanced. This is an exciting milestone, and I can’t wait to see what breakthroughs are on the horizon!
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 14/01/2025
Amazing!
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 12/01/2025
Less is more!
000
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 11/01/2025
My weekend essay inspired by a tough week of working with insurance. Two denials and one delayed treatment start. What is your experience with prior auths?
medium.com
Time Is Life: Why Oncology Patients Can’t Afford Prior Authorizations
Prior authorizations (PAs) have evolved from a cost-containment strategy into one of the most significant barriers in oncology care today. By delaying access to life-saving treatments, these…
182
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 11/01/2025
Congrats!
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 11/01/2025
Vasomotor symptoms from endocrine therapy are such a pain point. Glad to see advances in this space!
000
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 10/01/2025
Love it!
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 09/01/2025
lung and prostate cancer research (clinical outcomes) and phase III trials
031
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 09/01/2025
Always good reminder that’s where there is a will there is a way. *It also blows my mind that research funding for pediatric cancer is on chopping block with this new Congress. This is money well spent
050
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 08/01/2025
Using a negative PSMA PET scan to avoid surgery is like Faramir scouting the enemy’s movements in Ithilien. His vigilance prevents reckless attacks and ensures that Gondor’s forces act only when truly necessary. Strategic insight spares harm while achieving the mission. 🛡️🌿 #LOTRNerd #Prostatecancer
030
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 08/01/2025
This study suggests that a negative PSMA PET scan can help avoid unnecessary pelvic lymph node dissection in intermediate-risk prostate cancer patients, potentially reducing treatment complications without compromising outcomes. #ProstateCancer #MedicalImaging
nature.com
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer - Prostate Cancer and Prostatic Diseases
Prostate Cancer and Prostatic Diseases - Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer
162
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 08/01/2025
I think you need a space between your emoji and link to make it live and clickable
020
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 07/01/2025
Insurance denials and prior auths feel like trying to cross the Dead Marshes—every step forward is met with unseen obstacles dragging you down. Patients deserve a clear path to care, not to be lost in the bureaucracy. #Oncology #HealthcareFrustrations
020
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 06/01/2025
In oligometastatic spread aggressive source control (which should include transplant!)Can lead to amazing outcomes with durable responses. These lessons need to be emphasized across all tumor types.
010
Reposted by @drfranciscomd.bsky.social
Alun Ephraim @alunephraim.bsky.social · 06/01/2025
It used to be the case that transplants were never done in cases of cancer (and for tragically practical reasons), so that it is now occasionally possible is a major step forwards: www.bbc.co.uk/news/article...
bbc.co.uk
UK's first liver transplant for bowel cancer deemed a success
Bianca Perea, a 32-year-old trainee lawyer, is now
161
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 05/01/2025
Since most of our trial data comes from staging with conventional CT how do you reconcile upstaged prostate cancer with existing pathways?
000
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 05/01/2025
It’s the best field and entering its golden era! She won’t regret it!
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 04/01/2025
My first article. What is your opinion?
medium.com
In Defense of Doctors: Fighting the Epidemic of Mistrust
How Media, Misinformation, and a Broken System Are Undermining the Doctors Who Save Lives
130
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 02/01/2025
In Middle-earth terms, TXDX is like the Silmarils, forged by Fëanor to harness the light of the Two Trees. While originally intended for one purpose, their radiance became a beacon of hope for all of Arda. HER2-targeted therapy extends to multiple tumor types, illuminating new paths in cancer care🌟✨
020
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 02/01/2025
At #1 in our countdown: ‘Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors: Results From DESTINY-PanTumor02.’ This landmark trial expands the role of HER2-targeted therapy across multiple cancer types, marking a new frontier in precision medicine. 🧬✨ #OncologyPapers2024
ascopubs.org
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
PURPOSETrastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell...
120
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 01/01/2025
Organ preservation with neoadjuvant therapy is like Elrond healing Frodo with athelas after Weathertop—not removing Frodo’s arm but preserving it while targeting the Morgul wound. This precise approach spares what’s vital while addressing the source of the threat. 🌿🛡️ #LOTRNerd #OncologyWithPurpose
010
drfranciscomd.bsky.social @drfranciscomd.bsky.social · 01/01/2025
At #2 in our countdown: ‘Long-Term Results of Organ Preservation in Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The OPRA Trial.’ This study highlights a step forward in organ preservation, showing promising long-term outcomes with reduced treatment intensity. 🧬✨ #OncologyPapers2024
ascopubs.org
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or sec...
130